vs
Side-by-side financial comparison of FENNEC PHARMACEUTICALS INC. (FENC) and NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP (NEN). Click either name above to swap in a different company.
NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP is the larger business by last-quarter revenue ($23.6M vs $13.8M, roughly 1.7× FENNEC PHARMACEUTICALS INC.). FENNEC PHARMACEUTICALS INC. runs the higher net margin — -34.7% vs -677.3%, a 642.6% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs 15.7%). Over the past eight quarters, NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP's revenue compounded faster (8.9% CAGR vs -26.3%).
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
New England Realty Associates Limited Partnership is a real estate investment entity that owns, operates and manages residential and commercial properties primarily across the U.S. New England region. Its core assets include multifamily apartments, mixed-use properties and small commercial spaces, serving tenants across Massachusetts, New Hampshire and adjacent states, delivering steady returns to unitholders via rental income and property value growth.
FENC vs NEN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $23.6M |
| Net Profit | $-4.8M | $-1.4M |
| Gross Margin | — | — |
| Operating Margin | -18.5% | 14.0% |
| Net Margin | -34.7% | -677.3% |
| Revenue YoY | 73.8% | 15.7% |
| Net Profit YoY | -141.1% | -133.0% |
| EPS (diluted) | $-0.17 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $23.6M | ||
| Q3 25 | $12.5M | $23.7M | ||
| Q2 25 | $9.7M | $21.2M | ||
| Q1 25 | $8.8M | $20.7M | ||
| Q4 24 | $7.9M | $20.4M | ||
| Q3 24 | $7.0M | $20.2M | ||
| Q2 24 | $7.3M | $20.1M | ||
| Q1 24 | $25.4M | $19.9M |
| Q4 25 | $-4.8M | $-1.4M | ||
| Q3 25 | $-638.0K | $-521.8K | ||
| Q2 25 | $-3.2M | $4.1M | ||
| Q1 25 | $-1.2M | $3.8M | ||
| Q4 24 | $-2.0M | $4.2M | ||
| Q3 24 | $-5.7M | $3.9M | ||
| Q2 24 | $-5.6M | $4.1M | ||
| Q1 24 | $12.8M | $3.5M |
| Q4 25 | -18.5% | 14.0% | ||
| Q3 25 | -1.5% | 20.0% | ||
| Q2 25 | -28.3% | 33.3% | ||
| Q1 25 | -9.2% | 30.1% | ||
| Q4 24 | -11.8% | 32.4% | ||
| Q3 24 | -74.6% | 32.0% | ||
| Q2 24 | -69.4% | 32.6% | ||
| Q1 24 | 54.2% | 28.9% |
| Q4 25 | -34.7% | -677.3% | ||
| Q3 25 | -5.1% | -2.2% | ||
| Q2 25 | -32.7% | 19.5% | ||
| Q1 25 | -13.3% | 18.3% | ||
| Q4 24 | -25.0% | 20.7% | ||
| Q3 24 | -82.2% | 19.3% | ||
| Q2 24 | -76.5% | 20.3% | ||
| Q1 24 | 50.6% | 17.4% |
| Q4 25 | $-0.17 | — | ||
| Q3 25 | $-0.02 | — | ||
| Q2 25 | $-0.11 | — | ||
| Q1 25 | $-0.04 | — | ||
| Q4 24 | $-0.02 | — | ||
| Q3 24 | $-0.21 | — | ||
| Q2 24 | $-0.20 | — | ||
| Q1 24 | $0.41 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $36.8M | $26.7M |
| Total DebtLower is stronger | — | $531.0M |
| Stockholders' EquityBook value | $35.5M | — |
| Total Assets | $70.6M | $505.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $36.8M | $26.7M | ||
| Q3 25 | $21.9M | $13.4M | ||
| Q2 25 | $18.7M | $16.7M | ||
| Q1 25 | $22.7M | $30.9M | ||
| Q4 24 | $26.6M | $17.6M | ||
| Q3 24 | $40.3M | $15.1M | ||
| Q2 24 | $43.1M | $13.5M | ||
| Q1 24 | $51.2M | $28.8M |
| Q4 25 | — | $531.0M | ||
| Q3 25 | $19.4M | $514.2M | ||
| Q2 25 | $19.4M | $514.3M | ||
| Q1 25 | $19.4M | $407.8M | ||
| Q4 24 | $19.3M | $408.6M | ||
| Q3 24 | $32.1M | $409.3M | ||
| Q2 24 | $31.8M | $410.0M | ||
| Q1 24 | $31.3M | $410.7M |
| Q4 25 | $35.5M | — | ||
| Q3 25 | $-4.5M | — | ||
| Q2 25 | $-7.5M | — | ||
| Q1 25 | $-5.9M | — | ||
| Q4 24 | $-5.9M | — | ||
| Q3 24 | $-5.2M | — | ||
| Q2 24 | $-1.4M | — | ||
| Q1 24 | $3.0M | — |
| Q4 25 | $70.6M | $505.3M | ||
| Q3 25 | $49.3M | $492.9M | ||
| Q2 25 | $44.9M | $494.8M | ||
| Q1 25 | $46.4M | $385.2M | ||
| Q4 24 | $44.9M | $393.5M | ||
| Q3 24 | $58.9M | $387.4M | ||
| Q2 24 | $63.2M | $383.7M | ||
| Q1 24 | $69.2M | $381.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 10.40× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.0M | $27.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.0M | $27.7M | ||
| Q3 25 | $1.5M | $2.3M | ||
| Q2 25 | $-3.7M | $12.5M | ||
| Q1 25 | $-4.3M | $5.5M | ||
| Q4 24 | $-1.5M | $31.9M | ||
| Q3 24 | $-2.2M | $8.5M | ||
| Q2 24 | $-8.4M | $5.4M | ||
| Q1 24 | $39.0M | $6.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 3.02× | ||
| Q1 25 | — | 1.44× | ||
| Q4 24 | — | 7.57× | ||
| Q3 24 | — | 2.17× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | 3.04× | 1.77× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
